Andrew Gottesdiener

Andrew Gottesdiener is a Partner at Venrock, where he focuses on healthcare investments, particularly in the biotechnology and pharmaceuticals sectors, based in the firm's New York office. In his current role, he is responsible for sourcing, evaluating, and managing venture investments in early-stage life sciences companies, leveraging his deep expertise in biomedical science and business strategy.

Before becoming a partner, Andrew was a biotech investor at Venrock from 2017 to 2022, and he is also the Co-Founder and Board Member of Apogee Therapeutics, a biotechnology company founded in 2022. His career also includes advisory and research roles at McKinsey & Company, Insite, the Howard Hughes Medical Institute, and Rhythm Pharmaceuticals, reflecting a strong track record in venture capital and healthcare innovation.

Andrew holds an MD from Weill Cornell Medical College, an MBA from Columbia Business School, and an undergraduate degree from Washington University in St. Louis. He is recognized for combining clinical insight with investment acumen, making significant contributions to the biotechnology investment landscape through leadership positions and board engagements with growth-stage biopharma startups.